Published in Int J Oncol on August 01, 2003
Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res (2006) 2.46
Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin Cancer Res (2008) 1.96
Fluorescence lifetime imaging system for in vivo studies. Mol Imaging (2007) 1.83
Flow cytometric in situ proximity ligation analyses of protein interactions and post-translational modification of the epidermal growth factor receptor family. Cytometry A (2009) 1.73
Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA). Radiother Oncol (2008) 1.62
Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU Int (2005) 1.58
Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta (2007) 1.56
Potential of PET to predict the response to trastuzumab treatment in an ErbB2-positive human xenograft tumor model. J Nucl Med (2012) 1.52
[18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging (2007) 1.50
Liposomes, disks, and spherical micelles: aggregate structure in mixtures of gel phase phosphatidylcholines and poly(ethylene glycol)-phospholipids. Biophys J (2003) 1.43
Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res (2007) 1.40
Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules. J Nucl Med (2009) 1.33
111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med (2006) 1.32
First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule. J Nucl Med (2014) 1.31
EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol (2007) 1.28
The crosstalk between EGF, IGF, and Insulin cell signaling pathways--computational and experimental analysis. BMC Syst Biol (2009) 1.24
Physiochemical characterization of the Alzheimer's disease-related peptides A beta 1-42Arctic and A beta 1-42wt. FEBS J (2006) 1.14
HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair. Mol Cancer Ther (2008) 1.13
Direct observation and characterization of DMPC/DHPC aggregates under conditions relevant for biological solution NMR. Biochim Biophys Acta (2004) 1.12
Imaging prostate cancer: an update on positron emission tomography and magnetic resonance imaging. Curr Urol Rep (2010) 1.11
HER2- and EGFR-specific affiprobes: novel recombinant optical probes for cell imaging. Chembiochem (2010) 1.10
Quantitative analysis of Her2 receptor expression in vivo by near-infrared optical imaging. Mol Imaging (2010) 1.07
Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody. Bioconjug Chem (2005) 1.06
Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule. Nucl Med Biol (2007) 1.06
Boron neutron capture therapy for glioblastoma multiforme: clinical studies in Sweden. J Neurooncol (2003) 1.05
HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents. J Liposome Res (2008) 1.05
DESIGN OF LIPOSOMES CONTAINING PHOTOPOLYMERIZABLE PHOSPHOLIPIDS FOR TRIGGERED RELEASE OF CONTENTS. J Therm Anal Calorim (2009) 1.04
Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. Biochim Biophys Acta (2006) 1.04
Normal tissue protection for improving radiotherapy: Where are the Gaps? Transl Cancer Res (2012) 1.03
In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. Cancer Biother Radiopharm (2005) 1.03
'Image and treat': an individualized approach to urological tumors. Curr Opin Oncol (2010) 1.03
Biodistribution of 211At labeled HER-2 binding affibody molecules in mice. Oncol Rep (2007) 1.02
Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. Eur J Nucl Med Mol Imaging (2006) 1.02
Formation of transition metal-doxorubicin complexes inside liposomes. Biochim Biophys Acta (2002) 1.00
Radiolabeling of HER2 specific Affibody(R) molecule with F-18. J Fluor Chem (2008) 0.99
Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. J Nucl Med (2006) 0.99
Development of EGF-conjugated liposomes for targeted delivery of boronated DNA-binding agents. Bioconjug Chem (2002) 0.99
Effect of lipid headgroup composition on the interaction between melittin and lipid bilayers. J Colloid Interface Sci (2007) 0.99
Positron emission tomography/computed tomography and radioimmunotherapy of prostate cancer. Curr Opin Oncol (2009) 0.98
Affitoxin--a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors. J Immunother (2009) 0.98
68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET. Eur J Nucl Med Mol Imaging (2011) 0.97
Prostate specific membrane antigen- a target for imaging and therapy with radionuclides. Discov Med (2010) 0.97
Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes). J Control Release (2011) 0.96
PET/CT Imaging and Radioimmunotherapy of Prostate Cancer. Semin Nucl Med (2011) 0.95
pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol. Biochim Biophys Acta (2004) 0.95
SimBoolNet--a Cytoscape plugin for dynamic simulation of signaling networks. Bioinformatics (2009) 0.95
Docosahexaenoic acid stabilizes soluble amyloid-beta protofibrils and sustains amyloid-beta-induced neurotoxicity in vitro. FEBS J (2007) 0.94
In vivo fluorescence lifetime imaging monitors binding of specific probes to cancer biomarkers. PLoS One (2012) 0.94
Lactate release from adipose tissue and skeletal muscle in vivo: defective insulin regulation in insulin-resistant obese women. Am J Physiol Endocrinol Metab (2006) 0.94
All-or-none membrane permeabilization by fengycin-type lipopeptides from Bacillus subtilis QST713. Biochim Biophys Acta (2011) 0.94
Active targeting using HER-2-affibody-conjugated nanoparticles enabled sensitive and specific imaging of orthotopic HER-2 positive ovarian tumors. Small (2013) 0.93
Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with ¹²⁵I-EGF. PLoS One (2011) 0.93
Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity. J Pharm Sci (2005) 0.92
Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule. Biotechnol Appl Biochem (2009) 0.92
Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules. Protein Eng Des Sel (2010) 0.91
Formation of drug-arylsulfonate complexes inside liposomes: a novel approach to improve drug retention. J Control Release (2005) 0.91
Interactions between pH-sensitive liposomes and model membranes. Biophys Chem (2003) 0.91
Cellular effects of HER3-specific affibody molecules. PLoS One (2012) 0.91
Transition metal-mediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation. Pharm Res (2006) 0.90
Effects of lipid segregation and lysolipid dissociation on drug release from thermosensitive liposomes. J Control Release (2005) 0.90
Distribution of BPA and metabolic assessment in glioblastoma patients during BNCT treatment: a microdialysis study. J Neurooncol (2005) 0.89
Inverse treatment planning based on MRI for HDR prostate brachytherapy. Int J Radiat Oncol Biol Phys (2005) 0.89
HER2-affitoxin: a potent therapeutic agent for the treatment of HER2-overexpressing tumors. Clin Cancer Res (2011) 0.88
Sarcosine induces increase in HER2/neu expression in androgen-dependent prostate cancer cells. Mol Biol Rep (2011) 0.88
Morphology of magnetically aligning DMPC/DHPC aggregates-perforated sheets, not disks. Langmuir (2006) 0.88
Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation design, pharmacokinetics and efficacy. J Control Release (2010) 0.87
A novel 3D volumetric voxel registration technique for volume-view-guided image registration of multiple imaging modalities. Int J Radiat Oncol Biol Phys (2005) 0.87
[177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts. Cancer Res (2007) 0.87
In vivo method to monitor changes in HER2 expression using near-infrared fluorescence imaging. Mol Imaging (2012) 0.87
Generation and evaluation of bispecific affibody molecules for simultaneous targeting of EGFR and HER2. Bioconjug Chem (2012) 0.87
Disc formation in cholesterol-free liposomes during phase transition. Biochim Biophys Acta (2003) 0.87
Blocking EGFR in the liver improves the tumor-to-liver uptake ratio of radiolabeled EGF. Tumour Biol (2010) 0.87
An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes. J Control Release (2004) 0.87
Differences in radiosensitivity between three HER2 overexpressing cell lines. Eur J Nucl Med Mol Imaging (2008) 0.87
Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese. J Control Release (2005) 0.87
Influence of drug-to-lipid ratio on drug release properties and liposome integrity in liposomal doxorubicin formulations. J Liposome Res (2008) 0.86
HER-2--a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol (2002) 0.86
Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules. Eur J Nucl Med Mol Imaging (2008) 0.86
Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes. Int J Pharm (2007) 0.85
Polylactide-based paclitaxel-loaded nanoparticles fabricated by dispersion polymerization: characterization, evaluation in cancer cell lines, and preliminary biodistribution studies. J Pharm Sci (2014) 0.85
Quantification of internalization of EGFR-binding Affibody molecules: Methodological aspects. Int J Oncol (2010) 0.85
Melittin-lipid interaction: a comparative study using liposomes, micelles and bilayer disks. Biochim Biophys Acta (2008) 0.84
Accuracy of 3D volumetric image registration based on CT, MR and PET/CT phantom experiments. J Appl Clin Med Phys (2008) 0.84
[(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells. Eur J Nucl Med Mol Imaging (2005) 0.84
Comparing the epidermal growth factor interaction with four different cell lines: intriguing effects imply strong dependency of cellular context. PLoS One (2011) 0.84
Biological response to radiation therapy. Acta Oncol (2003) 0.84
Affibody-DyLight conjugates for in vivo assessment of HER2 expression by near-infrared optical imaging. PLoS One (2012) 0.84
Effects of phospholipid hydrolysis on the aggregate structure in DPPC/DSPE-PEG2000 liposome preparations after gel to liquid crystalline phase transition. Biochim Biophys Acta (2006) 0.84
Unilamellar vesicles obtained by simply mixing dioctadecyldimethylammonium chloride and bromide with water. Chem Phys Lipids (2006) 0.83
Tumor-cell targeted epiderimal growth factor liposomes loaded with boronated acridine: uptake and processing. Pharm Res (2003) 0.83
Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF. Eur J Nucl Med Mol Imaging (2003) 0.83
A novel 125I-labeled daunorubicin derivative for radionuclide-based cancer therapy. Nucl Med Biol (2006) 0.83